Combined inhibition of STAT3 and STAT5 by shRNAs also suppressed growth in chronic myeloid leukemia, suggesting that combinatorial suppression of STAT3 and STAT5 may be efficacious in treating hematological malignancies [230]. The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.